An evaluation of the acidogenic potential of asthma inhalers.
OBJECTIVE
The aims of the present study were firstly to investigate the inherent pH and titratable acidity of commercially available paediatric asthma inhalers in the United Kingdom and secondly to assess their in vivo acidogenic potential (saliva pH and plaque pH (PpH) tests) in a group of healthy adult volunteers.


METHODS
Manually actuated metered dose inhaler (MDI) and dry powder inhaler (DPI) formulations of all available preventor (glucocorticoids, disodium chromoglycate), reliever (beta(2) agonists) and combination asthma medication were investigated. The inherent pH and titratable acidity of 18 inhalers were determined and analysed using t-tests, ANOVA and post hoc Tukey's tests. Following this the oral pH responses after inhaler use were assessed in 14 healthy adult volunteers (complying with the FNDH criteria, 1985) who participated in a random blind study to determine both the salivary pH (SpH) and plaque pH following inhaler use. Non-parametric tests of significance (Mann-Whitney and Wilcoxon Signed-Ranked Tests) were used to analyse pH responses according to vehicle of delivery (MDI/DPI), lactose content and generic drug.


RESULTS
The inherent pH of the DPIs (n=8, mean pH=5.06) was significantly lower (P<0.005) than that of the MDIs (n=10, mean pH=6.45) and the titratable acidity of the lactose-based DPIs was twice that of the non-lactose-based DPIs (P<0.000). Lactose-based DPIs produced significantly lower salivary pH and plaque pH readings, greater maximum pH drops from baseline pH and larger areas below baseline pH in comparison with that of all other inhalers tested (P<0.05). All inhalers, however, failed to depress plaque pH below pH 6.


CONCLUSIONS
Although none of the inhalers were able to demonstrate an acidogenic response below the "critical" pH, the substantial pH drops observed with the lactose-based DPIs may be an important consideration for enamel demineralisation.
Child Dental Health, Leeds Dental Institute, Clarendon Way, Leeds LS2 9LU, UK.
R
R
Tootla
K J
KJ
Toumba
M S
MS
Duggal
D000318:Adrenergic beta-Agonists / Q000009:adverse effects; D018927:Anti-Asthmatic Agents / Q000009:adverse effects*; D001249:Asthma / Q000188:drug therapy*; D018592:Cross-Over Studies; D003773:Dental Plaque / Q000139:chemically induced / Q000737:chemistry*; D004337:Drug Carriers / Q000009:adverse effects*; D005938:Glucocorticoids / Q000009:adverse effects; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009330:Nebulizers and Vaporizers; D010865:Pilot Projects; D011208:Powders / Q000009:adverse effects; D012463:Saliva / Q000737:chemistry*
D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D004337:Drug Carriers; D005938:Glucocorticoids; D011208:Powders